1 |
Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci 2009;30:87-92.
DOI
|
2 |
Straker M. Clinical factors in tardive-dyskinesia. Psychiatr J Univ Ott 1980;5:28-33.
|
3 |
Rahiminejad F, Akhondzadeh S. Pharmacotherapy of schizophrenia: ploypharmacy approaches. Acta Med Iran 2010;48:203-208.
|
4 |
Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17:460-466.
DOI
|
5 |
Santamaría B, Pérez M, Montero D, Madurga M, de Abajo FJ. Use of antipsychotic agents in Spain through 1985-2000. Eur Psychiatry 2002;17:471-476.
DOI
ScienceOn
|
6 |
Micallef J, Fakra E, Blin O. [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale 2006;32(2 Pt 1):263-269.
DOI
ScienceOn
|
7 |
Acosta FJ, Aguilar EJ, Cejas MR, Gracia R. Beliefs about illness and their relationship with hopelessness, depression, insight and suicide attempts in schizophrenia. Psychiatr Danub 2013;25:49-54.
|
8 |
Kao YC, Liu YP. Suicidal behavior and insight into illness among patients with schizophrenia spectrum disorders. Psychiatr Q 2011;82: 207-220.
DOI
ScienceOn
|
9 |
Jovanovic N, Podlesek A, Medved V, Grubisin J, Mihaljevic-Peles A, Goran T, et al. Association between psychopathology and suicidal behavior in schizophrenia. A cross-sectional study of 509 participants. Crisis 2013;34:374-381.
DOI
|
10 |
Gorna K, Jaracz K, Wrzyszczynska L, Rybakowski F. Quality of life and depression in schizophrenic patients. Adv Med Sci 2007;52 Suppl 1:108-111.
|
11 |
Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24.
DOI
ScienceOn
|
12 |
Gaillard R, Ouanas A, Spadone C, Llorca PM, Loo H, Bayle FJ. [Benzodiazepines and schizophrenia, a review of the literature]. Encephale 2006;32(6 Pt 1):1003-1010.
DOI
ScienceOn
|
13 |
Bayle FJ, Blanc O, De Chazeron I, Lesturgeon J, Lancon C, Caci H, et al. [Pharmacological management of anxiety in patients suffering from schizophrenia]. Encephale 2011;37 Suppl 1:S83-S89.
DOI
ScienceOn
|
14 |
Rashkis HA, Smarr ER. Protection against reserpine-induced Parkinsonism. Am J Psychiatry 1957;113:1116.
DOI
ScienceOn
|
15 |
Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
DOI
ScienceOn
|
16 |
Rijcken CA, Monster TB, Brouwers JR, de Jong-van den Berg LT. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? J Clin Psychopharmacol 2003;23: 657-659.
DOI
ScienceOn
|
17 |
Shim IH, Woo YS, Jun TY, Kim KS, Bahk WM. Changes in antipsychotic drug usage in the psychiatric inpatients at a university hospital between 1997, 2003-2004 and 2009-2010. Korean J Psychopharmacol 2012;23:57-64.
|
18 |
Kwon JS, Kim ET, Ha TH, Roh KS, Choi JS, Kim YS. Drug prescribing patterns of outpatients with schizophrenia in a university hospital. J Korean Neuropsychiatr Assoc 2003;42:683-690.
|
19 |
Choi HJ, Jung SH, Kang MH, Lee JS, Bae JN, Kim CE. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean general hospital psychiatric unit: 2001 to 2008. Clin Psychopharmacol Neurosci 2011;9:17-22.
DOI
ScienceOn
|
20 |
Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58:1007-1010.
DOI
|
21 |
Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003;37:55-61.
DOI
ScienceOn
|
22 |
Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006; 20(6 Suppl):20-37.
DOI
|
23 |
Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 2012;12:20.
DOI
ScienceOn
|
24 |
Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010;71 Suppl 2:20-26.
DOI
ScienceOn
|
25 |
Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology 2003;28 Suppl 1:39-51.
|
26 |
Kwon JS, Ahn YM, Kim JH. Korean Medication Guideline for Schizophrenia 2006. Seoul: Korean Medication Algorithm Task Force for Schizophrenia;2006.
|
27 |
Roh D, Chang JG, Kim CH, Cho HS, An SK, Jung YC. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry 2014;48:52-60.
DOI
ScienceOn
|
28 |
Best-Shaw L, Gudbrandsen M, Nagar J, Rose D, David AS, Patel MX. Psychiatrists' Perspectives on Antipsychotic Dose and the Role of Plasma Concentration Therapeutic Drug Monitoring. Ther Drug Monit (in press).
|
29 |
Jung HJ, Kim D, Oh HY, Park YC. Patterns of delusions and hallucinations in schizophrenia: comparison between the 1990s and the 2000s. Korean J Biol Psychiatry 2013;20:80-85.
|
30 |
Oh HY, Kim D, Park YC. Nature of Persecutors and Their Behaviors in the Delusions of Schizophrenia: Changes between the 1990s and the 2000s. Psychiatry Investig 2012;9:319-324.
DOI
ScienceOn
|
31 |
Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010;67:255-262.
DOI
ScienceOn
|
32 |
Sim K, Lee NB, Chua HC, Mahendran R, Fujii S, Yang SY, et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. Br J Clin Pharmacol 2007;63:431-437.
DOI
ScienceOn
|